These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38787899)

  • 1. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
    Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
    PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
    Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
    BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.
    Ansaripour A; Uyl-de Groot CA; Redekop WK
    Pharmacoeconomics; 2018 Jan; 36(1):91-103. PubMed ID: 28795341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
    Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
    J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective.
    Ioannou SS; Marcou Y; Kakouri E; Talias MA
    Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32560485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
    Nguyen AQ; Tran OTM; Nguyen PK; Nguyen HT
    PLoS One; 2024; 19(3):e0300474. PubMed ID: 38489305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
    Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
    JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
    Takumoto Y; Shiroiwa T; Shimozuma K; Iwata H; Takahashi M; Baba S; Kobayashi K; Hagiwara Y; Kawahara T; Uemura Y; Mukai H; Taira N; Sawaki M
    Clin Drug Investig; 2022 Mar; 42(3):253-262. PubMed ID: 35233755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
    Lang HC; Chen HW; Chiou TJ; Chan AL
    J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil.
    Botelho CH; Estevez-Diz MDP; Campolina AG
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):63-72. PubMed ID: 34319216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
    Leung W; Kvizhinadze G; Nair N; Blakely T
    PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
    J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka.
    Gunasekara ADM; Youngkong S; Anothaisintawee T; Dejthevaporn T; Fernandopulle R; Chaikledkaew U
    Sci Rep; 2024 Jul; 14(1):16736. PubMed ID: 39033229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Trastuzumab Offer Good Value for Money for Breast Cancer Patients with Metastasis in Indonesia?
    Kristin E; Endarti D; Khoe LC; Pratiwi WR; Pinzon RT; Febrinasari RP; Yasmina A; Nugrahaningsih DAA; Taroeno-Hariadi KW; Karsono R; Sudarsa IW; Prenggono MD; Herlinawaty E; Komaryani K; Hidayat B; Nadjib M
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2441-2447. PubMed ID: 35901352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.